LENSAR Inc

LENSAR, Inc. is a commercial-stage medical device company that designs, develops, and markets laser systems for cataract treatment and for managing pre-existing or surgically induced corneal astigmatism. It operates in the United States, Europe, Asia, South Korea, and other international markets. Its products include the LENSAR Laser System, which uses proprietary technologies for imaging, procedure planning, design, and precision to support surgeons in achieving visual outcomes, and the ALLY Robotic Cataract Laser System, a compact system for sterile laser-assisted cataract surgery in a single operating room. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

LNSR▲2

LENSAR Q2 revenue rises 18% to $16.5 million

LENSAR reported second-quarter revenue growth of 18% to $16.5 million, driven by a 20% increase in recurring revenue to $13.7 million and a 23% increase in procedure revenue. GAAP net income reached $3.5 million, while adjusted EBITDA rose to a record $3.6 million. Procedure volume increased 13% year over year to 58,682, and U.S. market share reached 24.1%. The company placed 10 ALLY systems during the quarter, bringing the ALLY installed base to about 215 systems and total global installations to 445. Gross margin improved to about 59%, including a $1.1 million tariff-refund benefit, or 52% excluding it, and management expects margins in the low-50% range to be sustainable as recurring revenue grows.

LNSR ▲

MarketBeat·36dRead more →